Related Experiment Video
Updated: Jan 10, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
Nordic consensus document on Evolut FX+ transcatheter aortic valve implantation: optimizing index implantation and
Arif A Khokhar1, Mikko Savontaus2, Ahmed Al-Ani3
1Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Abstract:
Transcatheter aortic valve replacement (TAVI) is an established treatment strategy for patients with severe symptomatic aortic stenosis (AS). Multiple landmark randomized controlled trials have consistently demonstrated the safety, efficacy, and longer-term durability of the CoreValve/Evolut (Medtronic, MN, USA) transcatheter aortic valve (TAV) platform in treating severe AS. These findings have supported the expansion of TAVI to younger patients with longer life expectancy, in whom an optimized index valve implantation can significantly impact both acute procedural results and longer-term outcomes. In this technical narrative, we aim to describe how iterative changes in the latest-generation Evolut FX(+) TAV can be utilized to achieve an optimized index valve implantation.
More Related Videos
Related Concept Videos
Mitral Valve Prolapse II: Assessment and Management
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Atherosclerosis III: Management
Mitral Valve Prolapse III: Nursing Management

